Cardiac resynchronization therapy increases plasma levels of the endogenous inotrope apelin

European Journal of Heart Failure

Volumn 9, Issue 3, 2007, Pages 306-309

  Francia, Pietro ^a   Salvati, Adriano ^a   Balla, Cristina ^a   De Paolis, Paola ^c   Pagannone, Erika ^a   Borro, Marina ^a   Gentile, Giovanna ^a   Simmaco, Maurizio ^a   De Biase, Luciano ^a   Volpe, Massimo ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b IRCCS NEUROMED   (Italy)

^c FATEBENEFRATELLI HOSPITAL   (Italy)

Author keywords

Apelin; APJ; Heart failure; Neurohormones; NT proBNP; Resynchronization

Indexed keywords

APELIN; N TERMINAL PROHORMONE BRAIN NATRIURETIC PEPTIDE; PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; CLINICAL ARTICLE; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART EJECTION FRACTION; HEART FAILURE; HUMAN; INTERMETHOD COMPARISON; LONG TERM CARE; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SHORT COURSE THERAPY;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; CARDIAC PACING, ARTIFICIAL; CHRONIC DISEASE; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE, CONGESTIVE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; STROKE VOLUME; TREATMENT OUTCOME;

EID: 33847367028     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejheart.2006.06.005     Document Type: Article

References (9)

1. Molhoek S.G., Bax J.J., van Erven L., et al. Atrial and brain natriuretic peptides as markers of response to resynchronization therapy. Heart 90 1 (2004) 97-98
2. Braun M.U., Rauwolf T., Zerm T., et al. Long term biventricular resynchronization therapy in advanced heart failure: effect on neurohormones. Heart 91 5 (2005) 601-605
3. Berry M.F., Pirolli T.J., Jayasankar V., et al. Apelin has in vivo inotropic effects on normal and failing hearts. Circulation 110 11 Suppl 1 (2004) II187-II193
4. Ashley E.A., Powers J., Chen M., et al. The endogenous peptide apelin potently improves cardiac contractility and reduces cardiac loading in vivo. Cardiovasc Res. 65 1 (2005) 73-82
5. Szokodi I., Tavi P., Foldes G., et al. Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility. Circ Res 91 (2002) 434-440
6. Chong K.S., Gardner R.S., Morton J.J., Ashley E.A., and McDonagh T.A. Plasma concentrations of the novel peptide apelin are decreased in patients with chronic heart failure. Eur J Heart Fail (Feb 3 2006) (Electronic publication ahead of print)
7. Foldes G., Horkay F., Szokodi I., et al. Circulating and cardiac levels of apelin, the novel ligand of the orphan receptor APJ, in patients with heart failure. Biochem Biophys Res Commun 308 (2003) 480-485
8. Chen M.M., Ashley E.A., Deng D.X., et al. Novel role for the potent endogenous inotrope apelin in human cardiac dysfunction. Circulation 108 12 (2003) 1432-1439
9. Yu C.M., Fung J.W., Zhang Q., et al. Improvement of serum NT-proBNP predicts improvement in cardiac function and favourable prognosis after cardiac resynchronization therapy for heart failure. J Card Fail 11 5 Suppl (2005) S42-S46